Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627014 | 0.85 | NPSR1 (0.33) | — | |
| SCHEMBL14520768 | 0.80 | NPC1 (0.32) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13199356 | 0.78 | NPSR1 (0.35) | MAPTLMNATSHR | |
| SCHEMBL13627016 | 0.75 | NPSR1 (0.31) | — | |
| SCHEMBL2693261 | 0.71 | CYP1A2 (0.36) | MAPTLMNATDP1TSHR | |
| SCHEMBL28567915 | 0.69 | NPSR1 (0.40) | MAPTSMN1; SMN2LMNATDP1TSHR | |
| SCHEMBL13325298 | 0.68 | MAPT (0.31) | MAPT | |
| SCHEMBL2603177 | 0.65 | MAPT (0.30) | MAPT | |
| SCHEMBL14452692 | 0.64 | KIF11 (0.36) | NPC1TP53MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13593516 | 0.64 | MAPT (0.30) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615645-B2 | Method for the continuous production of aldehydes | BASF AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20070004939-A1 | Method for the continuous production of aldehydes | VOLLAND MARTIN | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004939-A1 | Method for the continuous production of aldehydes | HRH4, HRH2, HRH3 | NPC1 2155/4885TP53 2967/4885MAPT 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.